The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
Open accessAbstract
Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers, but the immunological mechanism and molecular determinants of primary and acquired resistance to TCEs remain poorly understood. Here, we identify conserved behaviors of bone marrow-residing T cells in multiple myeloma patients undergoing BCMAxCD3 TCE therapy. We show that the immune repertoire reacts to TCE therapy with cell state-dependent clonal expansion and find evidence supporting the coupling of tumor recognition via major histocompatibility complex class I (MHC class I), exhaustion, and clinical response. We find the abundance of exhausted-like CD8 + T cell clones to be associated with clinical response failure, and we describe loss of target epitope and MHC class I as tumor-intrinsic adaptations to TCEs. These findings advance our understanding of the in vivo mechanism of TCE treatment in humans and provide the rationale for predictive immune-monitoring and conditioning of the immune repertoire to guide future immunotherapy in hematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534
Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Human haematopoietic stem cell lineage commitment is a continuous process
Velten, L., Haas, S. F., Raffel, S., Blaszkiewicz, S., Islam, S., Hennig, B. P., Hirche, C., Lutz, C., Buss, E. C., Nowak, D., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3493 · Cited by 925
Baccin, C., Al-Sabah, J., Velten, L., Helbling, P. M., Grünschläger, F., Hernández-Malmierca, P., Nombela-Arrieta, C., Steinmetz, L. M., Trumpp, A., & Haas, S. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0439-6 · Cited by 904
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia
Baryawno, N., Przybylski, D., Kowalczyk, M. S., Kfoury, Y., Severe, N., Gustafsson, K., Kokkaliaris, K. D., Mercier, F., Tabaka, M., Hofree, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.040 · Cited by 884
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Bassez, A., Vos, H., Van Dyck, L., Floris, G., Arijs, I., Desmedt, C., Boeckx, B., Vanden Bempt, M., Nevelsteen, I., Lambein, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01323-8 · Cited by 867
CellRank for directed single-cell fate mapping
Lange, M., Bergen, V., Klein, M., Setty, M., Reuter, B., Bakhti, M., Lickert, H., Ansari, M., Schniering, J., Schiller, H. B., et al. (2022) · Nature Methods · doi:10.1038/s41592-021-01346-6 · Cited by 768
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Mogilenko, D. A., Shpynov, O., Andhey, P. S., Arthur, L., Swain, A., Esaulova, E., Brioschi, S., Shchukina, I., Kerndl, M., Bambouskova, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2020.11.005 · Cited by 683
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 653
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 576
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Oliveira, G., Stromhaug, K., Klaeger, S., Kula, T., Frederick, D. T., Le, P. M., Forman, J., Huang, T., Li, S., Zhang, W., et al. (2021) · Nature · doi:10.1038/s41586-021-03704-y · Cited by 558
Liu, B., Hu, X., Feng, K., Gao, R., Xue, Z., Zhang, S., Zhang, Y., Corse, E., Hu, Y., Han, W., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00292-8 · Cited by 473
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Seckinger, A., Delgado, J. A., Moser, S., Moreno, L., Neuber, B., Grab, A., Lipp, S., Merino, J., Prosper, F., Emde, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.002 · Cited by 312
Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans
Galletti, G., De Simone, G., Mazza, E. M. C., Puccio, S., Mezzanotte, C., Bi, T. M., Davydov, A. N., Metsger, M., Scamardella, E., Alvisi, G., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0791-5 · Cited by 299
Datlinger, P., Rendeiro, A. F., Boenke, T., Senekowitsch, M., Krausgruber, T., Barreca, D., & Bock, C. (2021) · Nature Methods · doi:10.1038/s41592-021-01153-z · Cited by 269
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Ledergor, G., Weiner, A., Zada, M., Wang, S.-Y., Cohen, Y. C., Gatt, M. E., Snir, N., Magen, H., Koren-Michowitz, M., Herzog-Tzarfati, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0269-2 · Cited by 263
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250
Dysfunctional T regulatory cells in multiple myeloma
Prabhala, R. H., Neri, P., Bae, J. E., Tassone, P., Shammas, M. A., Allam, C. K., Daley, J. F., Chauhan, D., Blanchard, E., Thatte, H. S., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3101 · Cited by 239
Self-citationFernández de Larrea, C., Staehr, M., Lopez, A. V., Ng, K. Y., Chen, Y., Godfrey, W. D., Purdon, T. J., Ponomarev, V., Wendel, H.-G., Brentjens, R. J., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0020 · Cited by 223
Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach
Laydon, D. J., Bangham, C. R. M., & Asquith, B. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0291 · Cited by 215
Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003805 · Cited by 182
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., et al. (2020) · Blood · doi:10.1182/blood.2019003342 · Cited by 174
Bailur, J. K., McCachren, S. S., Doxie, D. B., Shrestha, M., Pendleton, K., Nooka, A. K., Neparidze, N., Parker, T. L., Bar, N., Kaufman, J. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127807 · Cited by 171
Tirier, S. M., Mallm, J., Steiger, S., Poos, A. M., Awwad, M. H. S., Giesen, N., Casiraghi, N. A., Sušak, H., Bauer, K., Baumann, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26951-z · Cited by 159
Self-citationBortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Gullà, A., Morelli, E., Samur, M., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., PRABHALA, R. H., Talluri, S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0047 · Cited by 156
Co-evolution of tumor and immune cells during progression of multiple myeloma
Liu, R., Gao, Q., Foltz, S. M., Fowles, J. S., Yao, L., Wang, J. T., Cao, S., Sun, H., Wendl, M. C., Sethuraman, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22804-x · Cited by 150
Pillarisetti, K., Powers, G., Luistro, L., Babich, A., Baldwin, E., Li, Y., Zhang, X., Mendonça, M., Majewski, N., Nanjunda, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002393 · Cited by 144
Horton, B. L., Morgan, D. M., Momin, N., Zagorulya, M., Torres-Mejia, E., Bhandarkar, V., Wittrup, K. D., Love, J. C., & Spranger, S. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi8800 · Cited by 131
Meermeier, E. W., Welsh, S. J., Sharik, M. E., Du, M. T., Garbitt, V. M., Riggs, D. L., Shi, C., Stein, C. K., Bergsagel, M., Chau, B. H., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0038 · Cited by 120
Tumor‐specific CD 4+ T cells maintain effector and memory tumor‐specific CD 8+ T cells
Church, S., Jensen, S. M., Antony, P. A., Restifo, N. P., & Fox, B. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201343718 · Cited by 115
Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood · doi:10.1182/blood-2020-134063 · Cited by 112
Self-citationBispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 106
Frerichs, K. A., Broekmans, M. E. C., Marin Soto, J. A., van Kessel, B., Heymans, M. W., Holthof, L. C., Verkleij, C. P. M., Boominathan, R., Vaidya, B., Sendecki, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2299 · Cited by 94
Truger, M. S., Duell, J., Zhou, X., Heimeshoff, L., Ruckdeschel, A. M., John, M., Riedel, A., Hueper, S., Peter, J., Walter, W., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004418 · Cited by 92
Self-citationConnecting the Dots: Resolving the Bone Marrow Niche Heterogeneity
Dolgalev, I., & Tikhonova, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.622519 · Cited by 81
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1216 · Cited by 80
Alrasheed, N., Lee, L. S. H., Ghorani, E., Henry, J. Y., Conde, L., Chin, M., Galas‐Filipowicz, D., Furness, A. J. S., Chavda, S. J., Richards, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1714 · Cited by 75
Koike, M., Sekigawa, I., Okada, M., Matsumoto, M., Iida, N., Hashimoto, H., & Oshimi, K. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00192-8 · Cited by 71
Garfall, A. L., Usmani, S. Z., Mateos, M., Nahi, H., van de Donk, N. W. C. J., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Bhutani, M., et al. (2020) · Blood · doi:10.1182/blood-2020-138831 · Cited by 60
Bahlis, N. J., Raje, N. S., Costello, C., Dholaria, B. R., Solh, M. M., Levy, M. Y., Tomasson, M. H., Dube, H., Liu, F., Liao, K. H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8006 · Cited by 44
Self-citationFayon, M., Martínez-Cingolani, C., Abecassis, A., Roders, N., Nelson, E., Choisy, C., Talbot, A., Bensussan, A., Fermand, J., Arnulf, B., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.242453 · Cited by 36
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
Verkleij, C. P. M., Frerichs, K. A., Broekmans, M. E. C., Absalah, S., Maas-Bosman, P. W. C., Kruyswijk, S., Nijhof, I. S., Mutis, T., Zweegman, S., & van de Donk, N. W. C. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27792 · Cited by 35
Carpen, L., Falvo, P., Orecchioni, S., Mitola, G., Hillje, R., Mazzara, S., Mancuso, P., Pileri, S. A., Raveane, A., & Bertolini, F. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00893-x · Cited by 33
Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma
Zitvogel, L., & Kroemer, G. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0059 · Cited by 22
Multiple myeloma: altered CD4/CD8 ratio in bone marrow.
Redoglia, V., Boccadoro, M., Battaglio, S., Dianzani, U., Massaia, M., & Pileri, A. (1990) · PubMed · Cited by 21
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Self-citationLutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
Self-citationDandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2504719 · Cited by 5
Metadata
- Authors
- Friedrich, M. J., Neri, P., Kehl, N., Michel, J., Steiger, S., Kilian, M., Leblay, N., Maity, R., Sankowski, R., Lee, H., Barakat, E., Ahn, S., Weinhold, N., Rippe, K., Bunse, L., Platten, M., Goldschmidt, H., Müller-Tidow, C., Raab, M.-S., & Bahlis, N. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 41
- Issue
- 4
- Pages
- 711-725.e6
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4323656441
- Cited by
- 285
- References
- 54
- FWCI
- 50.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.